Clinical trial registry record

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 4, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06510816
Last registry update
May 4, 2026
Status
Active Not Recruiting
Phase
Phase 3
Sponsor
Annexon, Inc.
Enrollment
659
Countries
United States, Australia, Austria, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Spain, United Kingdom
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
659
Population
ALL · 50 Years
Duration
2024-07-30 to 2027-07-31
Intervention
Vonaprument; Sham Administration
Comparator
Not reported
Outcomes measured
Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Mon…; Time to Confirmed BCVA ≥15-letter Loss — Baseline to Month 15 and Baseline to Month 24; Proportion of Participants Experiencing a Confirmed BCVA ≥15-letter Loss — Baseline through Month 24; Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss — Baseline through Month 15 and Baseline thro…; Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer — Baseline, Month 15 and 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON